CUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cue Biopharma Inc (CUE) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak technical indicators, poor financial performance, and lacks significant positive catalysts. The absence of recent news, analyst ratings, or influential trading activity further diminishes its appeal. Given the investor's profile and goals, this stock does not align well with their strategy.
The stock exhibits bearish technical indicators. The MACD histogram is negative and contracting, the RSI is neutral at 39.392, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.301, with key resistance at 0.334 and support at 0.268. Overall, the technical outlook suggests no strong upward momentum.
NULL identified. No recent news, analyst upgrades, or significant trading activity from insiders, hedge funds, or politicians.
Weak financial performance in Q3 2025, with revenue down 35.58% YoY, net income down 14.00% YoY, and EPS down 58.82% YoY. Technical indicators are bearish, and there is no recent positive sentiment or trading activity to support the stock.
In Q3 2025, the company reported a 35.58% YoY decline in revenue to $2,149,000, a 14.00% YoY decline in net income to -$7,448,000, and a 58.82% YoY decline in EPS to -0.07. Gross margin remained stable at 100%. Overall, the financial performance indicates significant challenges in growth and profitability.
No data available for analyst ratings or price target changes.
